Utility of CAML as Diagnostic for Early Stage Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-21

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective Determine the prevalence of CAMLS in patients with pulmonary nodules.

Secondary Objectives Determine the positive and negative predictive value of CAMLS in patients with pulmonary nodules who undergo biopsy.

Model combinations of clinical factors with the presence/absence of CAMLS to refine strategies for assessment of patients with pulmonary nodules. Evaluate whether these measures result in enhanced T-cell activity and/or NK cell function and number

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Construction and Evaluation of the Liquid Biopsy-based Early Diagnostic Model for Lung Cancer

NCT04156360

Healthy Pulmonary Nodule

UNKNOWN

DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer

NCT02504697

Pulmonary Disease

ACTIVE_NOT_RECRUITING

The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer

NCT02380196

Non-small Cell Lung Cancer (NSCLC)

COMPLETED

Recurrent Predictive Power of Circulating Tumor Cells for Non Small Cell Lung Cancer Patients

NCT03721133

Lung Cancer Recurrent

ENROLLING_BY_INVITATION

A Multi-Center Trial of the ProLung Test™

NCT01566682

Solitary Pulmonary Nodule Multiple Pulmonary Nodules

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Nodule, Multiple Pulmonary Nodule, Solitary

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Referral for a pulmonary nodule that has not yet been biopsied and that meets the definition of an "indeterminate" nodules (i.e. 0.8-3.0 cm).
* No prior diagnosis of lung cancer or other invasive malignancy within the past 5 years.
* No history of rheumatologic disease.
* Age \> 18 years.
* Ability to understand and willingness to sign a written informed consent and HIPAA consent document

Exclusion Criteria

* Patients with active, known or suspected autoimmune disease.
* Prior diagnosis of lung cancer or other invasive malignancy within the past 5 years.
* Uncontrolled intercurrent illness that would increase the risk of toxicity or limit compliance with study requirements. This includes but is not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the abnormal immune response that results from HIV disease (testing is not required).
* Patients should be excluded if they are known to be positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection (testing is not required).
* Subjects with any history of interstitial lung disease or a history of \> or = to grade 2 radiation pneumonitis.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No